SFDA Penalizes Wandashan Pharmaceutical
This article was originally published in PharmAsia News
China's State FDA released its latest report on the lethal Ciwujia herbal injection produced by Wandashan Pharmaceutical, concluding that the incident is a severe adverse reaction caused by bacteria. According to investigation, the particular batch of Ciwujia was soaked by rain water leading to contamination, but the company's sales person in Yunnan changed the packaging labels and sold the product. SFDA concluded that Wandashan Pharmaceutical violated the Drug Administration Law and demanded the Heilongjiang FDA to suspend the company's production and withdraw its GMP authentication. Furthermore, Wandashan Pharmaceutical will be penalized in accordance with the relevant laws. Personnel responsible for the incident will be banned from drug production and distribution for 10 years. (Click here for more - Chinese Language)
You may also be interested in...
Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs
The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.
Manufacturers considering use of the popular 99.99% germ-kill claim on hand sanitizer products should consult the Office of Compliance, said Division of Nonprescription Drug Products director Theresa Michele during a recent industry workshop. “Be very, very cautious about the claims you are making,” she said.
Change in leadership at the European Medicines Agency comes at a critical time.